And colon cancer generic pills . Initiates Phase I Clinical Program for TG02Tragara Pharmaceuticals, announced the initiation of a Phase I clinical trial of TG02, a unique oral multi-kinase inhibitor, in patients with advanced / refractory hematologic malignancies. Tragara will conduct the study at multiple centers in the United States. In vitro and in vivo data of TG02 biological activity against acute leukemias and multiple myeloma in addition to several solid tumors with unmet medical needs also have demonstrated triple-negative breast cancer, non - small cell lung cancer and colon cancer. TG02 possesses a unique and exciting spectrum of kinase inhibitory capabilities Our preclinical the utility of the utility of inhibiting these different ways, and we are committed to investigate this potential in the clinic, said Thomas M. President and Chief Executive Officer, Tragara Pharmaceuticals, - TG02 an oral, small molecule kinase inhibitor with a pronounced inhibitory spectrum. TG02 is inhibits ERK5, Patients with relapsed cycle and transcriptional cyclin-dependent kinases , in a fashion equipotent at nanomolar concentrations. In preclinical models of leukemia, TG02 demonstrated that the combined inhibition of CDKs and JAK2/Flt3 signaling led to enhanced antitumor activity, said Sara Zaknoen, chief medical officer, Tragara Pharmaceuticals, In multiple myeloma, the addition of inhibition inhibition and the established roles of the JAK-STAT and CDK9 pathways in myeloma cell survival and drug resistance suggest that TG02 exciting addition to the exciting addition to the tools for this disease. .
Tragara will be phase I study phase I study by Ockham, a global contract research organization in Cary, North Carolina.About TG02TG02 is a novel, orally available, small molecule that targets - equipotently - the most important signal paths with ERK5, tumors.nd key cell cycle and transcriptional cyclin-dependent kinases , with excellent pharmacological and pharmaceutical properties. These pathways affect disease progression and survival in hematologic malignancies and solid tumors.
The report, 1990 to 2008 shows also below. - tens of of 87 countries to maternal mortality are the same or above 100 in the year 1990, is on the right way with a an annual decline of 5.5 percent. Study shows progress into sub-Saharan Africa, where maternal mortality fell by 26 percent. Will Asia the number of maternal deaths by estimated 315 thousand to 139 000 1,990 to 2008, fell a 52 percent drop. - 99 percent of all maternal deaths in the year 2008 stepped in the developing countries, to sub-Saharan Africa and Southern Asia accounting for 57 percent and 30 percent of deaths. - 'We must do even more further strengthen national strengthen national data collection systems,'says Dr. 'It is important to support include the development of complete and accurate civil registration system, births, deaths and death Every maternal deaths needs to be counted. Be, 'she adds.